Some deficiencies of this research are still worthy of in-depth exploration, including the failure to explain in depth how AR decoction interacts with Wnt5/β-catenin signals to treat CRC; and the failure to collect solid tumor samples from CRC patients receiving AR decoction treatment in China to verify the changes in Wnt5/β-catenin signal and the expression of ARF6 and N-Cadnerin in patients. This evidence concerns the gene ARF6 and colorectal carcinoma.